West Oak Capital LLC Raises Position in Bristol-Myers Squibb (NYSE:BMY)

West Oak Capital LLC lifted its stake in Bristol-Myers Squibb (NYSE:BMY) by 2,608.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 40,350 shares of the biopharmaceutical company’s stock after purchasing an additional 38,860 shares during the quarter. West Oak Capital LLC’s holdings in Bristol-Myers Squibb were worth $2,282,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of BMY. Graypoint LLC grew its position in Bristol-Myers Squibb by 41.7% in the 4th quarter. Graypoint LLC now owns 15,998 shares of the biopharmaceutical company’s stock valued at $905,000 after acquiring an additional 4,705 shares during the last quarter. Lynch & Associates IN grew its holdings in shares of Bristol-Myers Squibb by 6.3% in the fourth quarter. Lynch & Associates IN now owns 7,676 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 452 shares during the last quarter. Atlas Brown Inc. increased its stake in Bristol-Myers Squibb by 3.2% in the 4th quarter. Atlas Brown Inc. now owns 16,559 shares of the biopharmaceutical company’s stock worth $937,000 after buying an additional 518 shares during the period. Sage Capital Advisors llc lifted its holdings in Bristol-Myers Squibb by 1.0% during the 4th quarter. Sage Capital Advisors llc now owns 57,039 shares of the biopharmaceutical company’s stock valued at $3,226,000 after buying an additional 567 shares in the last quarter. Finally, LVM Capital Management Ltd. MI boosted its position in Bristol-Myers Squibb by 3.7% in the 4th quarter. LVM Capital Management Ltd. MI now owns 14,054 shares of the biopharmaceutical company’s stock valued at $795,000 after buying an additional 504 shares during the period. Institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This trade represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Samit Hirawat bought 1,830 shares of the stock in a transaction dated Friday, November 1st. The stock was bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the acquisition, the executive vice president now owns 62,109 shares in the company, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their position. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Trading Down 1.7 %

Shares of Bristol-Myers Squibb stock traded down $0.97 on Friday, reaching $55.84. The company had a trading volume of 9,677,613 shares, compared to its average volume of 10,010,127. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The firm’s 50 day moving average price is $57.41 and its two-hundred day moving average price is $51.34. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.08. The firm has a market cap of $113.25 billion, a PE ratio of -15.55, a PEG ratio of 15.20 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. The firm had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.00 earnings per share. Sell-side analysts predict that Bristol-Myers Squibb will post 0.93 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 4.44%. The ex-dividend date of this dividend is Friday, January 3rd. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is -69.08%.

Wall Street Analyst Weigh In

BMY has been the subject of several research analyst reports. Bank of America reaffirmed a “neutral” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Jefferies Financial Group upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and upped their target price for the stock from $63.00 to $70.00 in a report on Monday, December 16th. Morgan Stanley lifted their price objective on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. TD Cowen increased their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Finally, Sanford C. Bernstein assumed coverage on shares of Bristol-Myers Squibb in a report on Thursday, October 17th. They issued a “market perform” rating and a $56.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $56.27.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.